Ian T. Clark

Clark retired in 2016 as CEO of Genentech, where he and his team brought 11 new medicines to market for patients living with rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancers. He spent over two decades in the pharmaceutical industry in senior roles at Novartis, Ivax Pharma and Sanofi in the United Kingdom, France and Eastern Europe.

  • March 2022

Added to: Asher Biotherapeutics - So. San Francisco, CA

Asher Bio is biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.